Jump to Navigation

Publicaties 2003

  • Publicaties 2003:
  • Aleman BMP, Raemaekers JMM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert MLM, Keuning JJ, Carde P, Girinsky T, van der Maazen RWM, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, de Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WGJM, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M. Involved-field radiotherapy for advanced Hodgkin's lymphoma. NEW ENGL J MED 2003;348(24):2396-2406.     [ PubMed ]

 

  • Arens R. Balancing effector lymphocyte formation via CD27-CD70 interactions. S.l.: s.n.; 2003. (127pp.) (PhD thesis. Supervisor(s):  van Lier RAW, van Oers MHJ) [ UvA Dissertations Online ]

 

  • Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, dee R, van der Schoot CE, Delabesse E, Macintyre EA, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJM, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. LEUKEMIA 2003;17:2474-2486.  

 

  • Bollen JM, Polstra AM, van der Kuyl AC, Weel JF, Noorduyn LA, van Oers MHJ, Cornelissen M. Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report. BMC BLOOD DISORD 2003;3(1):3.     [ PubMed ]

 

  • Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JHF, Heemskerk MHM, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C. Safety of retroviral gene marking with a truncated NGF receptor. NAT MED 2003;9(4):367-369.     [ PubMed ]

 

  • de Gast GC, Batchelor D, Kersten MJ , Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. BRIT J CANCER 2003;88:175-180.  

 

  • de Haas M, van der Schoot CE, Overbeeke MAM, Koelewijn J, Bonsel GJ, Vrijkotte TJ. Current status of immunoprophylaxis with anti-D immunoglobulin - forum reply. VOX SANG 2003;85:333-334.  

 

  • de Jong D, Glas AM, Boerrigter L, Hermus MC, Dalesio O, Willemse E, Nederlof PM, Kersten MJ. Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. BLOOD 2003;102(1):324-327.  

 

  • Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MHH, van Oers MHJ, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GEG, Steijaert MMC, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J CLIN ONCOL 2003;21(16):3041-3050.     [ PubMed ]

 

  • Ebeling SB, Eric Borst HP, Simonetti ER, Hol S, Garin MI, Slaper-Cortenbach I, Hagenbeek A. Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene. J VIROL METHODS 2003;109(2):177-186.     [ PubMed ]

 

  • Ebeling SB, Ivanov R, Hol S, Aarts TI, Hagenbeek A, Verdonck LF, Petersen EJ. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells. BRIT J HAEMATOL 2003;121(5):721-729.     [ PubMed ]

 

  • Ebeling SB, Simonetti ER, Borst HPE, Blok A, Schelen AM, Braakman E, Ederveen J, Hagenbeek A. Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious. GENE THER 2003;10(21):1800-1806.     [ PubMed ]

 

  • Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, Rouger P, Morelati F, Tantalo V, Fujii T, de Haas M, van der Schoot CE, Overbeeke M, Koelewijn J, Bonsel G, Vrijkotte T, Zupańska B, Martin-Vega C, Parra Lopez R, de Silva M, Contreras M, Panzer S, Ulm B, Mayr WR. Current status of immunoprophylaxis with anti-D immunoglobin. VOX SANG 2003;85(4):328-337.     [ PubMed ]

 

  • Haas RLM, Poortmans P, de Jong D, Aleman BMP, Dewit LGH, Verheij M, Hart AAM, van Oers MHJ, van der Hulst M, Baars JW, Bartelink H. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J CLIN ONCOL 2003;21(13):2474-2480.     [ PubMed ]

 

  • Hagenbeek A. Minimal residual disease in lymphoma revisited. CLIN LYMPHOMA 2003;4(1):9.     [ PubMed ]

 

  • Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. LEUKEMIA LYMPHOMA 2003;44(Suppl. 4):S37-S47.     [ PubMed ]

 

  • Hagenbeek A, Bischof Delaloye A. Editorial perspective--advances in B-cell non-Hodgkin's lymphoma. LEUKEMIA LYMPHOMA 2003;44(Suppl. 4):S1-S4.     [ PubMed ]

 

  • Hazenberg MD, Borghans JAM, de Boer RJ, Miedema F. Thymic output: a bad TREC record. NAT IMMUNOL 2003;4(2):97-99.     [ PubMed ]

 

  • Hazenberg MD, Otto SA, Hamann D, Roos MTL, Schuitemaker H, de Boer RJ, Miedema F. Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS 2003;17(10):1419-1424.     [ PubMed ]

 

  • Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, Hamann D, Prins M, Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17(13):1881-1888.     [ PubMed ]

 

  • Hemker MB, Cheroutre G, van Zwieten R, Maaskant-van Wijk PA, Roos D, Loos JA, van der Schoot CE, von dem Borne AEGK. The Rh complex exports ammonium from human red blood cells. BRIT J HAEMATOL 2003;122(2):333-340.     [ PubMed ]

 

  • Kater AP , van Oers MHJ. Chronische lymfatische leukemie: hoog tijd voor een op het risico afgestemd beleid. NED TIJDSCHR GENEESKD 2003;147(3):104-110.     [ PubMed ]

 

  • Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. TUMOR BIOL 2003;24:53-60.  

 

  • Kolen S, Weijtens M, Hagenbeek A, van Spronsen A, Smulders S, de Weger R, de Witte T, Dolstra H, van de Wiel van Kemenade E, Martens A. Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells. HUM GENE THER 2003;14(4):341-351.     [ PubMed ]

 

  • Koopmans RP, van den Born BJ, Kersten MJ , Hart W. Klinisch denken en beslissen in de praktijk. Een 41-jarige man met onbegrepen periodieke koorts. NED TIJDSCHR GENEESKD 2003;147(37):1778-1783.     [ PubMed ]

 

  • Kumpel BM, de Haas M, Koene HR, van de Winkel JGJ, Goodrick MJ. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fc gamma RIIIa (CD16). CLIN EXP IMMUNOL 2003;132(1):81-86.  

 

  • Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MHJ, Barge RMY, Schouten HC, Westveer PHM, Steijaert MMC, Cornelissen JJ, Sonneveld P. Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM. J CLIN ONCOL 2003;21(9):1728-1733.     [ PubMed ]

 

  • Mackus WJM. Antigen receptor triggering and apotopic pathways in  neoplastic B cells. S.l.: s.n.; 2003. (139pp.) (ISBN 90-6734-049-92) (PhD thesis. Supervisor(s):  van Oers MHJ, van Lier RAW; co-supervisor(s):  Eldering EF) [ UvA Dissertations Online ]

 

  • Mackus WJM, Frakking FNJ, Grummels A, Gamadia LE, de Bree GJ, Hamann D, van Lier RAW, van Oers MHJ. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. BLOOD 2003;102(3):1057-1063.     [ PubMed ]

 

  • Mank A. De verzorging van centraal veneuze catheters: de ontwikkeling van een richtlijn. ONCOLOGICA 2003;20(1):6-12.

  

  • Mank A, Semin-Goossens A. Rituelen en evidence-based handelen in de verpleging: tegenstelling of aanvulling?.  In: van Beek CC, van Dorsten TC, editors. Handboek zorgvernieuwing. Houten: Bohn Stafleu Van Loghum; 2003. p. 1-43.

 

  • Mank A, Semin-Goossens A, de Ruyter R, van der Lelie J, Bakker PJM, de Vos R. Controle op overvulling bij hyperhydratie: wegen is betrouwbaarder dan notatie van de vochtbalans. VERPLEEGKUNDE 2003;18(3):149-158.  

 

  • Mank A, Semin-Goossens A, van der Lelie J, Bakker P, Vos R. Monitoring hyperhydration during high-dose chemotherapy: Body weight or fluid balance?. ACTA HAEMATOL-BASEL 2003;109(4):163-168.     [ PubMed ]

 

  • Mank A, Suyk L. Vochtbalans én wegen: noodzaak of gewoonte?. ONCOLOGICA 2003;20(4):202-205.  

 

  • Mank A, van der Lelie H. Is there still an indication for nursing patients with prolonged neutropenia in protective isolation? An evidence-based nursing and medical study of 4 years experience for nursing patients with neutropenia without isolation. EUR J ONCOL NURS 2003;7(1):17-23.     [ PubMed ]

 

  • Rijnders RJP, van der Luijt RB, Peters EDJ, Goeree JK, van der Schoot CE, Ploos van Amstel JK, Christiaens GCML. Earliest gestational age for fetal sexing in cell-free maternal plasma. PRENATAL DIAG 2003;23(13):1042-1044.     [ PubMed ]

 

  • Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG, Cornelissen JJ, Schaafsma MR, van Oers MHJ, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MMC, Buijt I, Lokhorst HM. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. BLOOD 2003;101(6):2144-2151.     [ PubMed ]

 

  • Spelten ER, Verbeek JHAM, Uitterhoeve ALJ, Ansink AC, van der Lelie J, de Reijke TM, Kammeijer M, de Haes JCJM, Sprangers MAG. Cancer, fatigue and the return of patients to work-a prospective cohort study. EUR J CANCER 2003;39(11):1562-1567.     [ PubMed ]

 

  • Tesselaar K, Arens R, van Schijndel GMW, Baars PA, van der Valk MA, Borst J, van Oers MHJ, van Lier RAW. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. NAT IMMUNOL 2003;4(1):49-54.     [ PubMed ]

 

  • van Agthoven M, Sonneveld P, Hagenbeek A, Uyl-de Groot CA. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. HEMATOL J 2003;4(6):399-409.     [ PubMed ]

 

  • van Buul JD, Voermans C, van Gelderen J, Anthony EC, van der Schoot CE, Hordijk PL. Leukocyte-endothelium interaction promotes SDF-1-dependent polarization of CXCR4. J BIOL CHEM 2003;278(32):30302-30310.     [ PubMed ]

 

  • van der Kolk LE, Grillo-López AJ, Baars JW, van Oers MHJ. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. LEUKEMIA 2003;17(8):1658-1664.     [ PubMed ]

 

  • van der Schoot CE, Tax GHM, Rijnders RJP, de Haas M, Christiaens GCML. Prenatal typing of Rh and Kell blood group system antigens: The edge of a watershed. TRANSFUS MED REV 2003;17(1):31-44.     [ PubMed ]

 

  • van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MCH, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens ACM, Ebeling SB. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. BLOOD 2003;102(7):2522-2531.     [ PubMed ]

 

  • van Rij RP, Hazenberg MD, van Benthem BHB, Otto SA, Prins M, Miedema F, Schuitemaker H. Early viral load and CD4(+) T cell count, but not percentage of CCR5(+) or CXCR4(+) CD4(+) T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS RES HUM RETROV 2003;19(5):389-398.     [ PubMed ]

 

  • van Staa TP, Boulton F, Cooper C, Hagenbeek A, Inskip H, Leufkens HGM. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. AM J HEMATOL 2003;72(4):248-254.     [ PubMed ]

 

  • Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ , Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal MWM, Horenblas S, de Gast GC. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. BRIT J CANCER 2003;88:1346-1351.

 

  • Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer AJM, Sulzer I, Hack CE, Wuillemin WA. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. CLIN DIAGN LAB IMMUN 2003;10(4):529-535.  

 

  • Zeerleder S, Zurcher Zenklusen R, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in meningococcal sepsis. Case 7. HAMOSTASEOLOGIE 2003;23(3):125-130.  

 

  • Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld ABJ, Caliezi C, van Nieuwenhuijze AEM, van Mierlo GJ, Eerenberg AJM, Lämmle B, Hack CE. Elevated nucleosome levels in systemic inflammation and sepsis. CRIT CARE MED 2003;31(7):1947-1951.     [ PubMed ]
Auteur: B.M.J.M. Odijk, versie: 0.0, 13-01-2022